Vicore Pharma - Interim report April-June 2023 Stockholm, August 24, 2023 - Vicore Pharma Holding AB (STO: VICO) (“Vicore”), unlocking the potential of a new class of drugs – angiotensin II type 2 receptor agonists (ATRAGs), publishes the interim report for the second quarter 2023.Important ev.
ATRAG formulations for lung disease europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.
Vicore announces the appointment of Ahmed Mousa as CEO New CEO to drive growth strategy to maximise potential of C21 as transformative treatment for idiopathic pulmonary fibrosis via the upcoming Phase 2b trialExperienced executive with a multi-disciplinary background and successful business development track r.
Vicore further strengthens patent protection for C21 Stockholm, June 7, 2023 – Vicore Pharma Holding AB (STO: VICO) (“Vicore”) today announces that the European Patent Office (EPO) has granted Vicore’s patent protecting an improved C21 formulation based on enteric coated compositions. Th.
Vicore Pharma Holding AB (STO:VICO) (“Vicore”) today announces issuance of a new US patent protecting an improved C21 formulation based on enteric coated compositions. The drug candidate C21 is currently in a phase 2a trial in idiopathic pulmonary fibrosis (IPF). The patent provides strong protection in the US .